• Age ≥ 18 years at the time of informed consent

• Patient must be able to provide informed consent, or a legal authorized representative (LAR) must be identified to provide consent in cases where the patient cannot

• Signed and dated IRB-approved Informed Consent Form

• Patient must have a histologically confirmed diagnosis of metastatic stage IV clear cell renal cell carcinoma or metastatic stage IV translocation-associated renal cell carcinoma.

• Patient should have availability of archival tissue that enables definitive diagnosis of ccRCC or tRCC, per review at participating site, accompanied by an associated pathology report. Specimens can be collected by surgical resection or biopsy of the primary tumor or biopsy or resection of a metastatic lesion. NOTE: If archival tissue is unavailable, a patient can still enroll onto the study with documented confirmation from the study PI.

• Patients must have at least one extra-skeletal, extracranial measurable lesion as defined by RECIST v1.1 7. Patients must have Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

• Patients must have progressed on at least 2 prior lines of systemic therapy and a maximum of 3 prior lines of systemic therapy. Prior adjuvant therapy is permitted.

• Patient must have progressed on 1 prior PD-1 or PD-L1 targeted treatment and prior VEGFR directed TKI therapy

• Patients must have recovered to baseline or \< Grade 1 CTCAE v5.0 from toxicities related to any prior treatments, unless adverse events (AEs) are clinically non-significant and/or stable on supportive therapy (See Appendix 2)

• Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and registration.

• The patient can swallow oral medications.

• Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to the first study treatment:

• ANC ≥ 1500 cells/μL (without granulocyte colony stimulating factor support within 2 weeks prior to Cycle 1, Day 1)

• WBC counts ≥ 2500/μL and ≤ 15,000/μL without G-CSF

• Absolute Lymphocyte count \<0.5K/mcL

• Platelet count ≥100,000/μL (without transfusion within 2 weeks prior to Cycle 1, Day 1)

• Hemoglobin ≥9.0 g/dL (without transfusion within 2 weeks prior to Cycle 1, Day 1)

• Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤ 3 X upper limit of normal (ULN). ALP ≤ 5 x ULN if patient has documented bone metastases.

• Serum bilirubin ≤ 1.5 x ULN. Patients with known Gilbert disease who have serum bilirubin level ≤ 2 x ULN may be enrolled.

• Serum albumin ≥ 2.8 g/dl

• (PT)/INR or partial thromboplastin time (PTT) test \< 1.3x the laboratory ULN

• Estimated Glomerular Filtration Rate (eGFR) ≥ 30mL/min using the CKD-EPI formula https://www.kidney.org/professionals/kdoqi/gfr\_calculator.

• Urine protein/creatinine ratio (UPCR) ≤ 1.8 mg/mg

• Women of childbearing potential must not be pregnant or lactating at screening.

• Women of childbearing potential who are sexually active with a non-sterilized male partner must use two methods of effective contraception from screening and must agree to continue using such precautions for 4 months after the final dose of investigational product; cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control.

• Sexually active participants must agree to use medically accepted methods of contraception (i.e. barrier methods including condoms, female condom, or diaphragm with spermicidal gel) during the study and for 4 months after the last dose of the study treatment. Male patients must agree not to donate sperm during the study treatment period and for 4 months after the last dose Female patients must agree not to donate eggs during the study period and for 4 months after the last dose.